-
Je něco špatně v tomto záznamu ?
A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma
P. Sonneveld, MA. Dimopoulos, M. Boccadoro, H. Quach, PJ. Ho, M. Beksac, C. Hulin, E. Antonioli, X. Leleu, S. Mangiacavalli, A. Perrot, M. Cavo, A. Belotti, A. Broijl, F. Gay, R. Mina, NWCJ. van de Donk, E. Katodritou, F. Schjesvold, AS. Balari,...
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, informační letáky pro pacienty
- MeSH
- bortezomib * aplikace a dávkování terapeutické užití MeSH
- dexamethason * aplikace a dávkování terapeutické užití MeSH
- dospělí MeSH
- klinické zkoušky, fáze II jako téma MeSH
- lenalidomid * aplikace a dávkování terapeutické užití MeSH
- lidé středního věku MeSH
- lidé MeSH
- mnohočetný myelom * farmakoterapie diagnóza MeSH
- monoklonální protilátky * aplikace a dávkování terapeutické užití MeSH
- protokoly protinádorové kombinované chemoterapie * terapeutické užití škodlivé účinky MeSH
- randomizované kontrolované studie jako téma MeSH
- senioři MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- informační letáky pro pacienty MeSH
WHAT IS THIS SUMMARY ABOUT?: This summary describes the first analysis of the PERSEUS study, which looked at adults with multiple myeloma that had never been treated before, also called newly diagnosed multiple myeloma. Multiple myeloma is a type of cancer in the blood, specifically in plasma cells within the soft, spongy tissue in the center of most bones, called the bone marrow. Researchers wanted to see if adding daratumumab (D) to a standard treatment of three other medicines called VRd, which stands for bortezomib (V), lenalidomide (R), and dexamethasone (d), could stop the multiple myeloma from getting worse and help participants live longer without multiple myeloma.Half of the participants were assigned to the treatment plan with daratumumab; they received D-VRd during initial treatment phases (induction and consolidation), followed by daratumumab as well as lenalidomide (D-R) in the maintenance phase. The other half of participants received treatment without daratumumab; they received VRd induction and consolidation followed by lenalidomide alone (R) maintenance. In addition, all participants were able to receive an autologous stem cell transplant, a procedure used to further help reduce multiple myeloma. WHAT WERE THE RESULTS?: At the time of this analysis of PERSEUS, about 4 years after participants started the study, participants who received D-VRd treatment followed by D-R maintenance had a better response to treatment (as measured by specific markers of multiple myeloma) and were more likely to be alive and free from their multiple myeloma getting worse in comparison to participants who received VRd followed by R maintenance. Side effects (unwanted or undesirable effects of treatment) in both treatment groups were in line with the known side effects of daratumumab and VRd. WHAT DO THE RESULTS MEAN?: The results of the PERSEUS study showed that including daratumumab in D-VRd induction/consolidation and D-R maintenance was better for treating multiple myeloma than the current standard VRd treatment followed by R maintenance alone in adults with a new diagnosis of multiple myeloma who were also able to receive an autologous stem cell transplant. Of importance, there were no unexpected side effects in either group.Clinical Trial Registration: NCT02874742 (GRIFFIN) (ClinicalTrials.gov).
Ankara University Ankara Turkey
CHU de Toulouse IUCT O Université de Toulouse UPS Service d'Hématologie Toulouse France
Department of Hematology ASST Spedali Civili di Brescia Brescia Italy
Department of Hematology Cancer Center Clínica Universidad de Navarra Pamplona Navarra Spain
Department of Hematology Careggi Hospital and University of Florence Firenze Italy
Department of Hematology EMN Erasmus MC Cancer Institute Rotterdam The Netherlands
Department of Hematology Hôpital Haut Lévêque University Hospital Pessac France
Department of Hematology Rigshospitalet Copenhagen Denmark
Department of Hematology Theagenion Cancer Hospital Thessaloniki Greece
Department of Internal Medicine 2 University Hospital Würzburg Würzburg Germany
Department of Medical Oncology and Hematology Cantonal Hospital St Gallen St Gallen Switzerland
Division of Hematology IRCCS Fondazione Policlinico San Matteo Pavia Italy
Genmab US Inc Plainsboro NJ USA
Hematology Department University Hospital Hôtel Dieu Nantes France
Hospital Clínic de Barcelona IDIBAPS Barcelona Spain
Janssen Research and Development Beerse Belgium
Janssen Research and Development LLC Beijing China
Janssen Research and Development LLC Leiden The Netherlands
Janssen Research and Development LLC Spring House PA USA
National and Kapodistrian University of Athens Athens Greece
University Medical Center Groningen Groningen The Netherlands
University of Leuven Leuven Belgium
University of Melbourne and St Vincent's Hospital Melbourne Australia
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc25004196
- 003
- CZ-PrNML
- 005
- 20250206110009.0
- 007
- ta
- 008
- 250121s2024 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1080/14796694.2024.2394323 $2 doi
- 035 __
- $a (PubMed)39287147
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Sonneveld, Pieter $u Department of Hematology, EMN/Erasmus MC Cancer Institute, Rotterdam, The Netherlands
- 245 12
- $a A plain language summary of the PERSEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for treating newly diagnosed multiple myeloma / $c P. Sonneveld, MA. Dimopoulos, M. Boccadoro, H. Quach, PJ. Ho, M. Beksac, C. Hulin, E. Antonioli, X. Leleu, S. Mangiacavalli, A. Perrot, M. Cavo, A. Belotti, A. Broijl, F. Gay, R. Mina, NWCJ. van de Donk, E. Katodritou, F. Schjesvold, AS. Balari, L. Rosiñol, M. Delforge, W. Roeloffzen, T. Silzle, A. Vangsted, H. Einsele, A. Spencer, R. Hajek, A. Jurczyszyn, S. Lonergan, T. Ahmadi, Y. Liu, J. Wang, D. Vieyra, EMJ. van Brummelen, V. Vanquickelberghe, A. Sitthi-Amorn, CJ. de Boer, R. Carson, P. Rodriguez-Otero, J. Bladé, P. Moreau
- 520 9_
- $a WHAT IS THIS SUMMARY ABOUT?: This summary describes the first analysis of the PERSEUS study, which looked at adults with multiple myeloma that had never been treated before, also called newly diagnosed multiple myeloma. Multiple myeloma is a type of cancer in the blood, specifically in plasma cells within the soft, spongy tissue in the center of most bones, called the bone marrow. Researchers wanted to see if adding daratumumab (D) to a standard treatment of three other medicines called VRd, which stands for bortezomib (V), lenalidomide (R), and dexamethasone (d), could stop the multiple myeloma from getting worse and help participants live longer without multiple myeloma.Half of the participants were assigned to the treatment plan with daratumumab; they received D-VRd during initial treatment phases (induction and consolidation), followed by daratumumab as well as lenalidomide (D-R) in the maintenance phase. The other half of participants received treatment without daratumumab; they received VRd induction and consolidation followed by lenalidomide alone (R) maintenance. In addition, all participants were able to receive an autologous stem cell transplant, a procedure used to further help reduce multiple myeloma. WHAT WERE THE RESULTS?: At the time of this analysis of PERSEUS, about 4 years after participants started the study, participants who received D-VRd treatment followed by D-R maintenance had a better response to treatment (as measured by specific markers of multiple myeloma) and were more likely to be alive and free from their multiple myeloma getting worse in comparison to participants who received VRd followed by R maintenance. Side effects (unwanted or undesirable effects of treatment) in both treatment groups were in line with the known side effects of daratumumab and VRd. WHAT DO THE RESULTS MEAN?: The results of the PERSEUS study showed that including daratumumab in D-VRd induction/consolidation and D-R maintenance was better for treating multiple myeloma than the current standard VRd treatment followed by R maintenance alone in adults with a new diagnosis of multiple myeloma who were also able to receive an autologous stem cell transplant. Of importance, there were no unexpected side effects in either group.Clinical Trial Registration: NCT02874742 (GRIFFIN) (ClinicalTrials.gov).
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 12
- $a monoklonální protilátky $x aplikace a dávkování $x terapeutické užití $7 D000911
- 650 12
- $a protokoly protinádorové kombinované chemoterapie $x terapeutické užití $x škodlivé účinky $7 D000971
- 650 12
- $a bortezomib $x aplikace a dávkování $x terapeutické užití $7 D000069286
- 650 12
- $a dexamethason $x aplikace a dávkování $x terapeutické užití $7 D003907
- 650 12
- $a lenalidomid $x aplikace a dávkování $x terapeutické užití $7 D000077269
- 650 12
- $a mnohočetný myelom $x farmakoterapie $x diagnóza $7 D009101
- 650 _2
- $a výsledek terapie $7 D016896
- 650 _2
- $a randomizované kontrolované studie jako téma $7 D016032
- 650 _2
- $a klinické zkoušky, fáze II jako téma $7 D017322
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a informační letáky pro pacienty $7 D029282
- 700 1_
- $a Dimopoulos, Meletios A $u National & Kapodistrian University of Athens, Athens, Greece
- 700 1_
- $a Boccadoro, Mario $u Myeloma Unit, Division of Hematology, University of Torino, Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino, Torino, Italy
- 700 1_
- $a Quach, Hang $u University of Melbourne & St. Vincent's Hospital, Melbourne, Australia
- 700 1_
- $a Ho, P Joy $u Institute of Haematology, Royal Prince Alfred Hospital & University of Sydney, Camperdown, NSW, Australia
- 700 1_
- $a Beksac, Meral $u Ankara University, Ankara, Turkey
- 700 1_
- $a Hulin, Cyrille $u Department of Hematology, Hôpital Haut Lévêque, University Hospital, Pessac, France
- 700 1_
- $a Antonioli, Elisabetta $u Department of Hematology, Careggi Hospital & University of Florence, Firenze, Italy
- 700 1_
- $a Leleu, Xavier $u University of Poitiers, CHU & Inserm 1313, Poitiers, France
- 700 1_
- $a Mangiacavalli, Silvia $u Division of Hematology, IRCCS Fondazione Policlinico San Matteo, Pavia, Italy
- 700 1_
- $a Perrot, Aurore $u CHU de Toulouse, IUCT-O, Université de Toulouse, UPS, Service d'Hématologie, Toulouse, France
- 700 1_
- $a Cavo, Michele $u IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia "Seràgnoli," Dipartimento di Medicina Specialistica, Diagnostica e Sperimentale, Università di Bologna, Bologna, Italy
- 700 1_
- $a Belotti, Angelo $u Department of Hematology, ASST Spedali Civili di Brescia, Brescia, Italy
- 700 1_
- $a Broijl, Annemiek $u Department of Hematology, EMN/Erasmus MC Cancer Institute, Rotterdam, The Netherlands
- 700 1_
- $a Gay, Francesca $u Division of Hematology 1, AOU Città della Salute e della Scienza di Torino, University of Torino & Department of Molecular Biotechnology & Health Sciences, University of Torino, Torino, Italy
- 700 1_
- $a Mina, Roberto $u Division of Hematology 1, AOU Città della Salute e della Scienza di Torino, University of Torino & Department of Molecular Biotechnology & Health Sciences, University of Torino, Torino, Italy
- 700 1_
- $a van de Donk, Niels W C J $u Department of Hematology, Amsterdam University Medical Center, Vrije Universiteit Amsterdam, Amsterdam, The Netherlands
- 700 1_
- $a Katodritou, Eirini $u Department of Hematology, Theagenion Cancer Hospital, Thessaloniki, Greece
- 700 1_
- $a Schjesvold, Fredrik $u Oslo Myeloma Center, Department of Hematology, Oslo University Hospital, Oslo, Norway, & KG Jebsen Center for B-cell Malignancies, University of Oslo, Oslo, Norway
- 700 1_
- $a Balari, Anna Sureda $u Hematology Department, Institut Català d'Oncologia - Hospitalet, IDIBELL, University of Barcelona, Barcelona, Spain
- 700 1_
- $a Rosiñol, Laura $u Hospital Clínic de Barcelona, IDIBAPS, Barcelona, Spain
- 700 1_
- $a Delforge, Michel $u University of Leuven, Leuven, Belgium
- 700 1_
- $a Roeloffzen, Wilfried $u University Medical Center Groningen, Groningen, The Netherlands
- 700 1_
- $a Silzle, Tobias $u Department of Medical Oncology & Hematology, Cantonal Hospital St. Gallen, St. Gallen, Switzerland
- 700 1_
- $a Vangsted, Annette $u Department of Hematology, Rigshospitalet, Copenhagen, Denmark
- 700 1_
- $a Einsele, Hermann $u Department of Internal Medicine II, University Hospital Würzburg, Würzburg, Germany
- 700 1_
- $a Spencer, Andrew $u Malignant Haematology & Stem Cell Transplantation Service, Alfred Health-Monash University, Melbourne, Australia
- 700 1_
- $a Hajek, Roman $u Department of Hematooncology, University Hospital Ostrava & Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic
- 700 1_
- $a Jurczyszyn, Artur $u Plasma Cell Dyscrasias Center, Department of Hematology, Jagiellonian University Medical College, Kraków, Poland
- 700 1_
- $a Lonergan, Sarah $u Department of Hematology, EMN/Erasmus MC Cancer Institute, Rotterdam, The Netherlands
- 700 1_
- $a Ahmadi, Tahamtan $u Genmab US, Inc., Plainsboro, NJ, USA
- 700 1_
- $a Liu, Yanfang $u Janssen Research & Development, LLC, Beijing, China
- 700 1_
- $a Wang, Jianping $u Janssen Research & Development, LLC, Spring House, PA, USA
- 700 1_
- $a Vieyra, Diego $u Janssen Research & Development, LLC, Spring House, PA, USA
- 700 1_
- $a van Brummelen, Emilie M J $u Janssen Research & Development, LLC, Leiden, The Netherlands
- 700 1_
- $a Vanquickelberghe, Veronique $u Janssen Research & Development, Beerse, Belgium
- 700 1_
- $a Sitthi-Amorn, Anna $u Janssen Research & Development, LLC, Spring House, PA, USA
- 700 1_
- $a de Boer, Carla J $u Janssen Research & Development, LLC, Leiden, The Netherlands
- 700 1_
- $a Carson, Robin $u Janssen Research & Development, LLC, Spring House, PA, USA
- 700 1_
- $a Rodriguez-Otero, Paula $u Department of Hematology, Cancer Center Clínica Universidad de Navarra, Pamplona, Navarra, Spain
- 700 1_
- $a Bladé, Joan $u Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, & Grupo Español de Mieloma-Programa Español de Tratamientos en Hematología (GEM/PETHEMA), Barcelona, Spain
- 700 1_
- $a Moreau, Philippe $u Hematology Department, University Hospital Hôtel-Dieu, Nantes, France
- 773 0_
- $w MED00008687 $t Future oncology $x 1744-8301 $g Roč. 20, č. 38 (2024), s. 3043-3063
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/39287147 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20250121 $b ABA008
- 991 __
- $a 20250206110004 $b ABA008
- 999 __
- $a ok $b bmc $g 2263746 $s 1240203
- BAS __
- $a 3
- BAS __
- $a PreBMC-MEDLINE
- BMC __
- $a 2024 $b 20 $c 38 $d 3043-3063 $e 20240917 $i 1744-8301 $m Future oncology $n Future Oncol $x MED00008687
- LZP __
- $a Pubmed-20250121
